The life science industry organization SwedenBIO pushed for stronger global collaborations on antimicrobial resistance (AMR) at the BIO International Convention in San Diego, U.S., earlier in June. The organization also
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
Immunicum announces corporate rebranding and name change to Mendus AB. The rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirations, states the company.
The two companies have announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders. Echosens and
Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen. The private placement enables acceleration of new projects in
Under the agreement, Zealand will contribute its expertise in peptide drug discovery to Iktos’ generative modelling technologies and expertise in machine learning and AI. “We are very pleased to join
NorthX Biologics is expanding into cell therapy manufacturing at its existing GMP-facility, as well as in premises at the Karolinska University Hospital campus in Stockholm. This initiative is part of
Elypta has announced the raise of 21 million USD in a series A financing round led by Bonnier Ventures. “The series A is a pivotal moment for Elypta as it
Most listed Swedish biotech companies have cash and financing that is sufficient to last until 2023 or longer. The few who do not have this should probably hurry while there
Solna District Court is convicting the surgeon Paolo Macchiarini for one case of causing bodily injury, serious crime. Macchiarini is found not guilty in two other cases and convicted to
Alvotech has announced that its ordinary shares and warrants will begin trading on the Nasdaq Stock Market LLC on Thursday, June 16, under the new ticker symbols “ALVO” and “ALVOW”,
The two companies have entered into an option and license agreement focused on the identification and development of novel antibodies for use in IO therapeutics. The collaboration is intended to
Olink Holding has announced that Finnish FinnGen will use Olink technology to provide detailed proteomics data to improve understanding of human health. FinnGen is a large-scale academic/industrial research collaboration in
There is a massive need for medicines and medical care in war-torn Ukraine, but getting aid supplies through is virtually impossible. At the same time, the Swedish healthcare service faces
TILT Biotherapeutics has completed the first close of its financing round raising 10.7 million USD. The round was led by Lifeline Ventures and was joined by Tesi (Finnish Industry Investment
Sponsored content
Veristat - A Scientific-Minded Global Clinical Research Organization
Veristat enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval.
With more than 27 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.
The COVID-19 pandemic
Sweden’s Minister of Health and Social Affairs, Lena Hallengren, has officially inaugurated Valneva Sweden’s new COVID-19 vaccine manufacturing facility, the first and only one of its kind in Sweden. “The
Bavarian Nordic has provided an update on the Phase 3 development of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. The upcoming Phase 3 trial has been redesigned to include
New research from Karolinska Institutet shows that a booster shot of mRNA vaccine to individuals who have received two doses of inactivated vaccine offers the same level of protection against
Several months after COVID-19, one is still at an increased risk of blood clot and bleeding, shows research from Umeå University. The researchers analyzed all COVID-19 cases in Sweden from the
Residential exposure to ambient air pollutants is linked to an elevated risk of SARS-CoV-2 infection, an observational study of young adults in Stockholm, Sweden shows. The study was conducted by
Drug and device development
Targovax has entered into a clinical trial collaboration agreement with Oslo University Hospital (OUS) to run a phase 1/2 study testing polyvalent mutant RAS vaccine TG01 in multiple myeloma (MM)
AlzeCure Pharma has announced that the first patient has been included in a Phase II clinical trial with ACD440, a non-opioid drug candidate in the Painless platform which is being
Ultimovacs has announced positive 2-year overall survival data in its ongoing phase I clinical study of the cancer vaccine UV1 in combination with pembrolizumab for the treatment of malignant melanoma.
The last of 38 study participants were treated with Supernitro on 18 May, and the substance has shown good safety and tolerability. No unexpected side effects have been reported. At
Aqilion has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has approved the company’s Phase 1 clinical trial with its drug candidate AQ280. Aqilion applied
Profile
Malin Parkler, CEO of Pfizer Sweden, is driven by curiosity and a passion to build knowledge and evolve the life science industry – with the ultimate goal to yield real
In a new job
In her new role as Chief Executive Officer at Medicon Valley Alliance, Anette Steenberg aims to zoom in on the strongholds of the region as well as strengthening the framework
Valur Ragnarsson has been appointed as Chairman of the Board by Coripharma’s Board of Directors. Valur is a pharmaceutical executive with a solid track record spanning over 30 years, driving
Orion Corporation’s Board of Directors has appointed Liisa Hurme as President and CEO of Orion Corporation and the Chair of the Executive Management Board of the Orion Group as of
Careers
Hedvig Andersén talks about her job as an Investment Manager at Industrifonden. “The hardest thing, but also the most exciting, is that you’re investing in the people who are running the businesses.
Read the latest issue of our magazine!
No 02 2022 // This issue includes in-depth articles about successful company growth within life sciences. What lessons can we learn from the journeys, progress, setbacks and challenges of other Nordic companies? What perspectives and advice can the region’s investors and business advisors provide?
In addition, Jutta Heix, Head of International Affairs at Oslo Cancer Cluster, describes how she is accelerating the development of new cancer treatments and diagnostics – connecting and helping innovators and putting Norwegian oncology on the global map, and Bengt Mattson, special adviser at Lif, writes about health in the shadow of war. We take a closer look at four different career choices within drug discovery; their daily tasks, what challenges they encounter and what drives them in their different roles.
This, and much more, in our latest issue – out now!
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
Since its inception in 2013, NLSDays has nurtured a community of people from the world of life science, and created a unique place to do business. This annual event offers an informal
This event is scheduled as a 3 day in-person event in Leipzig, October 24-26, and a 3 day virtual event, November 2-4. This year the event will be held in
At Outsourcing in Clinical Trials and Clinical Trial Supply Nordics the pharmaceutical, biotechnology, and medical device communities need to come together and discuss strategies for operational success in clinical trials.
Both MEDICA 2022 and COMPAMED 2022 will reflect the entire medical technology value and process chains and present a comprehensive range of medical products, devices and instruments. In 2021, both
The latest research news from the Nordic region
Science Article
Solna District Court is convicting the surgeon Paolo Macchiarini for one case of causing bodily injury, serious crime. Macchiarini is found not guilty in two other cases and convicted to
Scientists at Karolinska Institutet and Stockholm University have visualized in detail the machinery that the mitochondria use to form their proteins. The mitochondria convert energy locked in our food into
Researchers at Karolinska Institutet have identified a new vaccine candidate against pneumococci, bacteria that can cause pneumonia, sepsis, and meningitis. The vaccine molecules comprise nano-sized membrane vesicles produced by the
In March 2022, the Wallenberg foundations announced financial support for the employment of Ukrainian scientists at Swedish universities. Following the launch of an open call targeting the SciLifeLab research environment,
Scientists at deCODE genetics have together with their Nordic collaborators published the largest genome-wide association study to date on rheumatoid arthritis (RA), including over thirty thousand cases and one million
The Nobel Laureates in Medicine 2021 revealed the mechanisms that underpin the different sensations of temperature and touch. Their discoveries have led to a better understanding of how the nervous
Nordic Life Science
The latest clinical trials
AlzeCure Pharma has announced that the first patient has been included in a Phase II clinical trial with ACD440, a non-opioid drug candidate in the Painless platform which is being
Ultimovacs has announced positive 2-year overall survival data in its ongoing phase I clinical study of the cancer vaccine UV1 in combination with pembrolizumab for the treatment of malignant melanoma.
The last of 38 study participants were treated with Supernitro on 18 May, and the substance has shown good safety and tolerability. No unexpected side effects have been reported. At
Aqilion has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has approved the company’s Phase 1 clinical trial with its drug candidate AQ280. Aqilion applied
Lytix Biopharma has announced data from its ATLAS-IT-04 trial in patients with metastatic soft tissue sarcoma (STS). The data from this Phase II proof of concept study shows that LTX-315
AlzeCure Pharma has received approval from the regulatory authorities in Sweden to initiate its clinical phase IIa study with the drug candidate ACD440 in patients with peripheral neuropathic pain. ”We
Gedea Biotech has received regulatory approval from the Ethics Committee and the Swedish Medical Products Agency and will start the EpHect clinical study of its lead product, pHyph, a vaginal
EpiEndo Pharmaceuticals has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects. EP395 is the first of EpiEndo’s orally available, non-antibiotic macrolides or ‘Barriolides’
Immunicum has announced updated interim results from the ongoing ADVANCE II clinical trial evaluating the company’s lead development program DCP-001, a novel therapeutic option for acute myeloid leukemia (AML) maintenance
Sign up to our newsletter